Grover Rajiv
Aesthet Surg J. 2006 Jan-Feb;26(1S):S18-21. doi: 10.1016/j.asj.2005.09.002.
Restylane SubQ has been developed to meet the growing demand for minimally invasive cosmetic procedures that correct loss of facial soft tissue volume and provide a nonpermanent solution for facial rejuvenation. This new product in the Restylane product family is based on the same non-animal stabilized hyaluronic acid (NASHA) gel as all other Restylane products, but contains larger gel particles than existing products. This characteristic allows for optimal volume expansion when injected subcutaneously or supraperiostally. Possible indications for Restylane SubQ include cheek augmentation in young patients with flat malar bone as an alternative to cheek implants. Other indications could be midface rejuvenation in patients who either feel it is too early for a face lift, or who are ready for a face lift but are unwilling to undergo surgery. Another possible use could be chin augmentation-pure augmentation as an alternative to chin implantation, or simply rejuvenation of the chin profile to enhance projection in patients with early chin ptosis. A common principle in all these possible indications is that the aesthetic outcome obtained with Restylane SubQ largely depends on appropriate patient selection and counseling. Facial tissue structure is an important consideration when selecting patients for treatment with Restylane SubQ, since treatment success is dependent on adequate soft-tissue cover for the injected product, as well as soft tissue support to prevent mobility.
瑞蓝SubQ的研发旨在满足人们对微创美容手术日益增长的需求，这些手术可纠正面部软组织容量流失，并为面部年轻化提供非永久性解决方案。瑞蓝产品系列中的这款新产品与所有其他瑞蓝产品一样，基于相同的非动物稳定透明质酸（NASHA）凝胶，但所含凝胶颗粒比现有产品更大。这一特性使得在皮下或骨膜上注射时能够实现最佳的容量扩张。瑞蓝SubQ的可能适应症包括为颧骨扁平的年轻患者进行脸颊填充，作为脸颊植入物的替代方案。其他适应症可能是那些认为进行面部提升为时过早的患者，或者那些准备好进行面部提升但不愿接受手术的患者的中面部年轻化。另一种可能的用途是下巴填充——单纯填充作为下巴植入的替代方案，或者仅仅是改善下巴轮廓，以增强早期下巴下垂患者的前突度。所有这些可能适应症的一个共同原则是，使用瑞蓝SubQ获得的美学效果在很大程度上取决于适当的患者选择和咨询。在选择使用瑞蓝SubQ进行治疗的患者时，面部组织结构是一个重要的考虑因素，因为治疗成功取决于为注射产品提供足够的软组织覆盖，以及防止移动的软组织支撑。
